Microbix & Copan Italia Execute Strategic Agreement | 2020-12-21 | Push Releases

MISSISSAUGA, Ontario and BRESCIA, Italy, Dec. 21, 2020 (Globe NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF, Microbix &circledR ), a daily life sciences innovator and exporter, and Copan Italia S.p.A. (Copan &circledR ), the world-wide chief in specimen selection systems, announce their execution of a strategic settlement (Settlement) in relation to Microbix&CloseCurlyQuotes quality assessment merchandise (QAPs™) and Copan&CloseCurlyQuotes flocked devices (FLOQ &circledR ).

The Arrangement amongst Microbix and Copan expands upon an present buy and supply contract, including licensing of Copan&CloseCurlyQuotes issued patents for use of flocked products to format test controls (broadly recognized as QAPs). Also, it formalizes the parties&CloseCurlyQuote agreement for joint use of their respective models for internet marketing of novel and revolutionary QAPs – Combining Copan&CloseCurlyQuotes perfectly-regarded FLOQ &circledR model with Microbix&CloseCurlyQuotes emerging PROCEEDx™ (RUO) and REDx™ (IVD) brand names – to use PROCEEDx™ FLOQ &circledR and REDx™ FLOQ&circledR as around the world branding for active co-marketing of top-edge FLOQSwab-formatted QAPs by Microbix and Copan.

Twelve such FLOQ-centered QAPs SKUs have previously been created and introduced into just one or far more of Australia, Canada, the European Union, Scandinavia, the United States, or the United Kingdom. Of those, thoroughly IVD-controlled REDxFLOQ controls are now out there to support lab-dependent molecular-test workflows for the SARS-CoV-2 virus (the trigger of COVID-19 sickness). Microbix also intends to license/sign up REDxFLOQ variations of its rising PROCEEDxFLOQ portfolio, together with for workflow aid of SARS-CoV-2 antigen tests, Flu A, Flu B, and RSV, then for other pathogen tests for which affected individual samples are gathered on FLOQSwabs. To date, approximately 50,000 units of FLOQSwab-based QAPs have been bought.

Stefania Triva, CEO of Copan, commented, “We&CloseCurlyQuoteve been performing with the Microbix staff for some time now and the mutual have confidence in that has been developed has led to an agreement that will broadly aid the diagnostics business. Furthermore and as a end result of our collaboration with Microbix, Copan FLOQ products are now starting to be identified as the ideal way of supporting lab excellent management system goals, as considerably as Copan FLOQSwab-based mostly products and solutions are the chosen usually means of individual-sample selection.&CloseCurlyDoubleQuote

Cameron Groome, CEO & President of Microbix, remarked, “We&CloseCurlyQuotere honoured that Copan is entrusting us to signify the FLOQ brand via our progressive and proprietary QAPs. We think the collaboration among our businesses will improve lab tests precision in international locations all over the globe – not just through the present-day pandemic, but for numerous decades to appear. Also, we thank Stefania and the Copan technical, operational, business, and lawful teams for their perform on this arrangement – it proceeds to be a enjoyment.&CloseCurlyDoubleQuote

About Microbix Biosystems

Microbix develops proprietary biological and engineering solutions for human overall health and perfectly-being, with about 80 proficient workers and sales growing from a base of somewhere around $1 million per thirty day period. It will make a broad array of significant organic materials for the worldwide diagnostics business, notably antigens for immunoassays and its laboratory quality assessment items (QAPs™) that help medical lab proficiency tests, permit assay improvement and validation, or aid make sure the quality of scientific diagnostic workflows. Microbix antigens help the antibody checks of above 100 global diagnostics businesses, though its QAPs are bought to scientific laboratory accreditation organizations, diagnostics corporations, and scientific laboratories. Microbix QAPs are now available in over 20 countries, dispersed by Alpha-Tec Devices, Inc., Diagnostic Global Distribution S.p.A., Labquality Oy, The Medical Source Business of Eire, and R-Biopharm AG. Microbix is ISO 9001 and 13485 accredited, U.S. Fda registered, Australian TGA registered, Health Canada institution accredited, and provides CE marked products.

Microbix also applies its organic know-how and infrastructure to produce other proprietary items and technologies, most notably viral transportation media to stabilize affected person samples for lab-centered molecular diagnostic tests and Kinlytic &circledR urokinase, a biologic thrombolytic drug applied to take care of blood clots. Microbix is traded on the TSX and OTCQB, and headquartered in Mississauga, Ontario, Canada.

About Copan Italia S.p.A. and Copan Group

Established in 1979 by the late Giorgio Triva, Copan Italia S.p.A. is based in Brescia, Italy and has subsidiaries in all continents, with production operations in Italy, the United States, and China. Copan has come to be the world wide chief in specimen assortment, transportation, and automated workflow units, obtaining made a suite of merchandise that revolutionized bacteriology, virology, and molecular biology exam pre-analytics based mostly on the patented FLOQSwab &circledR technology. Further more data about Copan Group is offered on its site, www.copangroup.com .

Ahead-On the lookout Information and facts

This information release contains “forward-wanting details,&CloseCurlyDoubleQuote as such expression is outlined in applicable securities regulations. Ahead-on the lookout information and facts includes, without limitation, all dialogue regarding the referenced Arrangement, Copan or the sights of its associates, Microbix&CloseCurlyQuotes company and organization effects, objectives or outlook, pitfalls associated with monetary outcomes and steadiness, growth tasks this kind of as people referenced in its company presentation, regulatory compliance and approvals, product sales to domestic or overseas jurisdictions, engineering and design, production (such as regulate more than expenditures, high-quality, quantity and timeliness of shipping and delivery), international forex and trade charges, maintaining adequate doing the job money and elevating further more cash on suitable terms or at all, and other very similar statements concerning predicted foreseeable future functions, conditions or effects that are not historical points. These statements mirror management&CloseCurlyQuotes current estimates, beliefs, intentions and expectations they are not assures of potential overall performance. The Enterprise cautions that all ahead on the lookout information is inherently unsure and that actual functionality may perhaps be afflicted by a amount of product elements, lots of of which are further than the Enterprise&CloseCurlyQuotes command. Appropriately, genuine long run gatherings, conditions and outcomes might differ materially from the estimates, beliefs, intentions and anticipations expressed or implied in the forward-on the lookout details. All statements are designed as of the day of this information launch and signify the Enterprise&CloseCurlyQuotes judgement as of the date of this new release, and the Business is below no obligation to update or alter any ahead-seeking details.

Please visit www.microbix.com or www.sedar.com for recent Microbix news and filings.

For further more details, you should speak to Microbix at:

Cameron Groome, CEO

(905) 361-8910
Jim Currie, CFO

(905) 361-8910
Deborah Honig, Trader Relations

Adelaide Funds Markets

(647) 203-8793 [email protected]

Copyright © 2020 Microbix Biosystems Inc.

Microbix &circledR , Kinlytic &circledR , PROCEEDx™, QAPs™, and REDx™ are logos of Microbix Biosystems Inc.

COPAN &circledR , FLOQ &circledR , and FLOQSwab &circledR are trademarks of Copan Italia S.p.A.

PROCEEDx™FLOQ &circledR and REDx™FLOQ &circledR are emblems of Microbix Biosystems Inc. in collaboration with Copan Italia S.p.A.

Primary Logo